Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients
The analysis of pre- and post-vaccination B-cell-associated cytokines might be useful in predicting the immunogenicity of seasonal trivalent influenza vaccine (TIV) in solid organ transplant (SOT) recipients. We performed a subanalysis of a clinical trial that compared the safety and efficacy of high-dose intradermal (ID) versus intramuscular (IM) TIV in SOT recipients. Serum levels of selected cytokines (interferon [IFN]-γ, interleukin [IL]-2, IL-4, IL-5, IL-6, IL-12 and IL-21, and tumor necrosis factor [TNF]-α) were measured pre- and one month post-vaccination in 155 patients (with 84 and 71 receiving the ID and IM vaccines, respectively). Cytokine profiles were compared according to vaccine response (seroconversion [≥4-fold increase in hemagglutination inhibition antibody titers] to ≥1 influenza vaccine antigen). Mean baseline IL-6 levels were higher (1.20 versus 0.65pg/mL; P-value=0.021) and IL-2 levels were lower (0.01 versus 0.50pg/mL; P-value=0.051) in patients achieving vaccine response. After adjusting for clinical variables, baseline IL-6/IL-2 ratio remained predictive of vaccine response (odds ratio per 10-unit increment: 1.06; 95% confidence interval: 1.02-1.10; P-value=0.002). Vaccination induced an increase in TNF-α (P-value <0.0001) and a decrease in IL-5 levels (P-value=0.0007). There were no significant differences in cytokine kinetics between vaccine responders and non-responders. Mean baseline TNF-α levels were higher in patients experiencing moderate-to-severe adverse events after vaccination (1.93 versus 1.72pg/mL; P-value=0.009). Baseline serum IL-6 and IL-2 levels, two cytokines that modulate the role of CD4(+) T follicular helper cells and the terminal differentiation of B-cells, predict vaccine response in SOT recipients..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Vaccine - 33(2015), 51, Seite 7176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernández-Ruiz, Mario [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.vaccine.2015.10.134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956704493 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956704493 | ||
| 003 | DE-627 | ||
| 005 | 20230714141733.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2015.10.134 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956704493 | ||
| 035 | |a (DE-599)GBVOLC1956704493 | ||
| 035 | |a (PRQ)p1638-eb87372a40f0909eedf1ec53a483e40ed2b248045a8a31524bad617e5d6a1e30 | ||
| 035 | |a (KEY)0128923320150000033005107176baselineseruminterleukin6tointerleukin2ratioisasso | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The analysis of pre- and post-vaccination B-cell-associated cytokines might be useful in predicting the immunogenicity of seasonal trivalent influenza vaccine (TIV) in solid organ transplant (SOT) recipients. We performed a subanalysis of a clinical trial that compared the safety and efficacy of high-dose intradermal (ID) versus intramuscular (IM) TIV in SOT recipients. Serum levels of selected cytokines (interferon [IFN]-γ, interleukin [IL]-2, IL-4, IL-5, IL-6, IL-12 and IL-21, and tumor necrosis factor [TNF]-α) were measured pre- and one month post-vaccination in 155 patients (with 84 and 71 receiving the ID and IM vaccines, respectively). Cytokine profiles were compared according to vaccine response (seroconversion [≥4-fold increase in hemagglutination inhibition antibody titers] to ≥1 influenza vaccine antigen). Mean baseline IL-6 levels were higher (1.20 versus 0.65pg/mL; P-value=0.021) and IL-2 levels were lower (0.01 versus 0.50pg/mL; P-value=0.051) in patients achieving vaccine response. After adjusting for clinical variables, baseline IL-6/IL-2 ratio remained predictive of vaccine response (odds ratio per 10-unit increment: 1.06; 95% confidence interval: 1.02-1.10; P-value=0.002). Vaccination induced an increase in TNF-α (P-value <0.0001) and a decrease in IL-5 levels (P-value=0.0007). There were no significant differences in cytokine kinetics between vaccine responders and non-responders. Mean baseline TNF-α levels were higher in patients experiencing moderate-to-severe adverse events after vaccination (1.93 versus 1.72pg/mL; P-value=0.009). Baseline serum IL-6 and IL-2 levels, two cytokines that modulate the role of CD4(+) T follicular helper cells and the terminal differentiation of B-cells, predict vaccine response in SOT recipients. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Ltd. All rights reserved. | ||
| 650 | 4 | |a IQR | |
| 650 | 4 | |a seroconversion factor | |
| 650 | 4 | |a coefficient of variation | |
| 650 | 4 | |a TNF | |
| 650 | 4 | |a solid organ transplantation | |
| 650 | 4 | |a T follicular helper cell | |
| 650 | 4 | |a Gangrene | |
| 650 | 4 | |a MMF | |
| 650 | 4 | |a tumor necrosis factor | |
| 650 | 4 | |a intradermal | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a TIV | |
| 650 | 4 | |a IFN | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a germinal center | |
| 650 | 4 | |a interquartile range | |
| 650 | 4 | |a adverse event | |
| 650 | 4 | |a Immunoglobulins | |
| 650 | 4 | |a Immunoassay | |
| 650 | 4 | |a hemagglutinin | |
| 650 | 4 | |a interleukin-6 receptor | |
| 650 | 4 | |a SCF | |
| 650 | 4 | |a confidence interval | |
| 650 | 4 | |a cell | |
| 650 | 4 | |a hemagglutination inhibition | |
| 650 | 4 | |a Abbreviations | |
| 650 | 4 | |a interleukin | |
| 650 | 4 | |a Tumor necrosis factor-TNF | |
| 650 | 4 | |a HAI | |
| 650 | 4 | |a LLOQ | |
| 650 | 4 | |a SEM | |
| 650 | 4 | |a standard error of the mean | |
| 650 | 4 | |a Confidence intervals | |
| 650 | 4 | |a trivalent inactivated vaccine | |
| 650 | 4 | |a Interferon | |
| 650 | 4 | |a mycophenolate mofetil | |
| 650 | 4 | |a Standard deviation | |
| 650 | 4 | |a lowest limit of quantification | |
| 650 | 4 | |a odds ratio | |
| 650 | 4 | |a SOT | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a IL-6R | |
| 650 | 4 | |a intramuscular | |
| 700 | 1 | |a Humar, Atul |4 oth | |
| 700 | 1 | |a Baluch, Aliyah |4 oth | |
| 700 | 1 | |a Keshwani, Shanil |4 oth | |
| 700 | 1 | |a Husain, Shahid |4 oth | |
| 700 | 1 | |a Kumar, Deepali |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d Amsterdam : Elsevier, 1983 |g 33(2015), 51, Seite 7176 |w (DE-627)130402427 |w (DE-600)605674-X |w (DE-576)015904938 |x 0264-410X |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:51 |g pages:7176 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.vaccine.2015.10.134 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26555352 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1746587123 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 51 |h 7176 | ||